Health: Merck Didn’t Get Keytruda TNBC Approval

The Story:

Earlier this year, the giant New Jersey based pharma firm Merck & Co. tried, but failed, to get accelerated approval from the US Food and Drug Administration for the use of Keytruda in cases of triple negative breast cancer (TNBC).  The setback may be a sign that the FDA is hardening its line against quick approvals for what are known as immuno-oncology agents.


In many breast cancers, the cells in the tumors have one or more of three receptors that make them vulnerable to chemotherapy. In the case of triple-negative breast cancer, on the other hand, treatment is complicated by the absence of any of the receptors. It makes chemo a smaller part of the overall treatment, and makes surgery a larger part. Merck wanted to sell Keytruda as part of the chemo that both precedes and follows surgery in TNBC situations.

In late February, a panel of ten experts unanimously ruled that Merck must wait for longer-term data from its trial before asking the FDA for approval.

In Pill Form:

Keytruda is the brand name — the chemical name is pembrolizumab. It is used at present on many forms of cancer. It is, for example, a first-line treatment for metastatic non-small cell lung carcinoma. The Merck now has a sizeable investment riding on its availability for TNBC and will presumably continue pressing the point if the further trial results allow.



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.